Trial Profile
A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms FALCON
- Sponsors Blue Earth Diagnostics
- 27 Sep 2021 Post-hoc analysis results published in Blue Earth Diagnostics Media Release.
- 27 Sep 2021 According to an Blue Earth Diagnostics media release, post-hoc analysis of data from the prospective LOCATE and FALCON were presented at the Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer
- 15 Feb 2020 Results (n=65) assessing impact on salvage radiotherapy decisions in men post-radical prostatectomy, presented at the 2020 Genitourinary Cancers Symposium.